AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that the Company and its investigators will be presenting results from the Phase 3 SAP302 study of ARX-04 (sufentanil sublingual tablet, 30 mcg) in 76 patients who were treated for moderate-to-severe acute pain in the emergency department. An oral presentation reviewing these results, including the types of injuries that were sustained by patients in the study, will be made at the International Society for Burn Injuries (ISBI), which is taking place August 29 – September 1 in Miami, Florida.
As previously reported, adult patients treated with ARX-04 in this study experienced a mean pain intensity difference of 2.9 from a baseline of 8.1 on a validated 0 – 10 numeric rating scale at 60 minutes, meeting the study’s primary objective. Injuries sustained by patients in SAP302 included fractures, sprains/strains, lacerations and burns, among others. Study participants tolerated ARX-04 well, with nausea (9%), somnolence (5%) and vomiting (4%) comprising the most commonly reported adverse events.
The study additionally concluded that ARX-04 had no overall impact on cognitive function. (Original Source)
Shares of Acelrx closed last Friday at $3.21, down $0.03 or -0.93%. ACRX has a 1-year high of $5.88 and a 1-year low of $2.40. The stock’s 50-day moving average is $3.31 and its 200-day moving average is $3.34.
On the ratings front, ACRX has been the subject of a number of recent research reports. In a report issued on August 24, Jefferies analyst Eun Yang reiterated a Buy rating on ACRX. Separately, on August 17, H.C. Wainwright’s Ed Arce reiterated a Buy rating on the stock .
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Eun Yang and Ed Arce have a total average return of 1.5% and 5.1% respectively. Yang has a success rate of 59.3% and is ranked #1284 out of 4127 analysts, while Arce has a success rate of 30% and is ranked #939.
The street is mostly Bullish on ACRX stock. Out of 4 analysts who cover the stock, 3 suggest a Buy rating and one recommends to Hold the stock.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of therapies for the treatment of actual pain. Its lead product candidate includes ZalvisoTM intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system. It is designed to address the problems associated with post-operative intravenous patient-controlled analgesia, or IV PCA.